Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Isoleucyl-tRNA synthetase (IleRS) is an essential enzyme responsible for attaching isoleucine to its corresponding tRNA, ensuring accurate protein synthesis. It employs a double-sieve editing mechanism to prevent misincorporation of similar amino acids like valine. IleRS is a potential therapeutic target, especially in autoimmune diseases due to its association with autoantibodies.
Inhibition of isoleucine-tRNA charging, leading to disruption of protein synthesis
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Isoleucyl-tRNA Synthetase (IleRS).